LKFT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LK

Mkt Cap

$1.96B

Volume

241.62K

Loading chart

LK

LKFTLakefront Biotherapeutics American Depositary Shares

LKFT

Pay with—

Available Balance0.00

LK

Mkt Cap

$1.96B

Volume

241.62K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell TherapeuticsLakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics for €8 million upfront plus up to $230 million in milestone payments and royalties. The sale marks the substantial completion of Lakefront's previously announced wind-down of legacy cell therapy activities, allowing the company to focus on its newly established T-cell engager pipeline while shareholders retain potential upside from future progress.GlobeNewswire Inc. · Oct 14, 2026

Lakefront kondigt de verkoop aan van haar preklinische CAR-T-programma’s aan Armed Cell TherapeuticsLakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for an €8 million upfront payment plus up to $230 million in milestone payments and royalties. The transaction marks the near-completion of Lakefront's previously announced wind-down of cell therapy activities, allowing the company to focus on its T-cell engager pipeline while providing shareholders potential upside from Armed Cell's future progress.GlobeNewswire Inc. · Oct 14, 2026

Lakefront Receives Transparency Notification from Bank of AmericaBank of America Corporation has crossed the 10% voting rights threshold in Lakefront Biotherapeutics following the acquisition of voting rights and equivalent financial instruments. As of August 18, 2026, Bank of America owns 1,419,144 direct voting rights (2.15%) and 5,243,453 equivalent financial instruments (7.96%), totaling 10.11% of Lakefront's 65,897,071 outstanding shares.GlobeNewswire Inc. · Aug 24, 2026

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of PemphigusLakefront Biotherapeutics announced that the FDA has granted Orphan Drug Designation to gamgertamig for treating pemphigus, expanding on previous Fast Track and Orphan Drug designations for autoimmune hemolytic anemia and immune thrombocytopenia. The drug, developed in collaboration with Gilead Sciences, is currently in Phase 1b trials with expansion anticipated in 2027 and registrational studies expected in 2027.GlobeNewswire Inc. · Aug 24, 2026

to start trading

LK

LKFTLakefront Biotherapeutics American Depositary Shares

LKFT

Pay with—

Available Balance0.00

Your PositionYou don't own any LKFT yet.

Related Tickers

Earnings